Antisoma, sanofi-aventis sales and marketing update

sanofi-aventis acquired exclusive, U.S. rights to Oforta fludarabine from Antisoma for $60 million in cash up front plus $5 million over five years. The oral purine nucleoside analog was approved last December in the U.S. as second-line therapy to treat B cell chronic lymphocytic leukemia (B CLL). ...